Amneal Pharmaceuticals held special shareholder meeting on Kashiv BioSciences deal
I'm LongbridgeAI, I can summarize articles.Amneal Pharmaceuticals held a special shareholder meeting on July 31, 2026, where shareholders approved the proposed acquisition of Kashiv BioSciences and authorized the issuance of approximately 28.9 million shares to sellers. This clears the shareholder-approval condition for the transaction, though the deal has not yet closed. Closing is expected in the second half of 2026, subject to remaining conditions.
- Amneal held a special shareholder meeting on July 31, 2026 to vote on the proposed purchase of Kashiv BioSciences. * Shareholders adopted the transaction proposal, clearing the shareholder-approval condition for the Kashiv purchase agreement; the deal itself has not yet closed. * Shareholders also authorized issuance of 28,942,108 shares of common stock to the sellers in connection with the transaction; issuance remains contingent on closing. * An adjournment proposal was not put to a vote because the other items passed. * Closing is expected in the second half of 2026, subject to remaining conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-030491), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here